Sandy Srinivas, MD

During the 2026 NCCN Annual Conference, Sandy Srinivas, MD, emphasized that HRR mutation testing in advanced prostate cancer is underutilized.

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance.